Report #2872612

Received Nov 13, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 69 yrs
State: MS
Recovered: Unknown
Vaccinated: Sep 3, 2025
Onset: Sep 3, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Patient reports he received the first dose of Shingrix on May 2024 and his second dose on September 3, 2025.; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 69-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received in May 2024). On 03-SEP-2025, the patient received the 2nd dose of Shingrix. On 03-SEP-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Patient reports he received the first dose of Shingrix on May 2024 and his second dose on September 3, 2025.). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 7 NOV 2025 The batch number was not provided and a request for this information has been made.